WallStreetZenWallStreetZen

NASDAQ: FDMT
4d Molecular Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for FDMT

Based on 5 analysts offering 12 month price targets for 4d Molecular Therapeutics Inc

Min Forecast
$26.00+173.97%
Avg Forecast
$32.40+241.41%
Max Forecast
$38.00+300.42%

Should I buy or sell FDMT stock?

Based on 5 analysts offering ratings for 4d Molecular Therapeutics Inc.

Strong Buy
Strong Buy
4 analysts 80%
Buy
1 analysts 20%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although FDMT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates FDMT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their FDMT stock forecasts and price targets.

FDMT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-28
lockedlocked$00.00+00.00%2025-12-18
lockedlocked$00.00+00.00%2025-11-11
lockedlocked$00.00+00.00%2025-11-11
lockedlocked$00.00+00.00%2025-08-12

1 of 1

Forecast return on equity

Is FDMT forecast to generate an efficient return?

Company
-64.23%
Industry
337.03%
Market
215.3%
FDMT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is FDMT forecast to generate an efficient return on assets?

Company
-55.9%
Industry
118.5%
FDMT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

FDMT earnings per share forecast

What is FDMT's earnings per share in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$3.55
Avg 2 year Forecast
-$3.52
Avg 3 year Forecast
-$3.98

FDMT revenue forecast

What is FDMT's revenue in the next 3 years based on estimates from 11 analysts?

Avg 1 year Forecast
$20.7M+17,120%
Avg 2 year Forecast
$21.8M+18,029.17%
Avg 3 year Forecast
$35.2M+29,267.5%
FDMT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

FDMT revenue growth forecast

How is FDMT forecast to perform vs Biotechnology companies and vs the US market?

Company
544.33%
Industry
118.38%
Market
23.25%
FDMT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
FDMT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

FDMT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
FDMT$9.49$32.40+241.41%Strong Buy
LYEL$25.77$32.50+26.12%Strong Buy
LXEO$7.52$20.17+168.18%Strong Buy
RGNX$10.86$34.50+217.68%Strong Buy
DNA$8.79$10.50+19.45%Hold
View Top Biotech Stocks

4d Molecular Therapeutics Stock Forecast FAQ

Is 4d Molecular Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: FDMT) stock is to Strong Buy FDMT stock.

Out of 5 analysts, 4 (80%) are recommending FDMT as a Strong Buy, 1 (20%) are recommending FDMT as a Buy, 0 (0%) are recommending FDMT as a Hold, 0 (0%) are recommending FDMT as a Sell, and 0 (0%) are recommending FDMT as a Strong Sell.

If you're new to stock investing, here's how to buy 4d Molecular Therapeutics stock.

What is FDMT's earnings growth forecast for 2026-2028?

(NASDAQ: FDMT) 4d Molecular Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.56%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.96%.

4d Molecular Therapeutics's earnings in 2026 is -$209,177,000.On average, 11 Wall Street analysts forecast FDMT's earnings for 2026 to be -$202,743,814, with the lowest FDMT earnings forecast at -$240,767,206, and the highest FDMT earnings forecast at -$155,978,755. On average, 10 Wall Street analysts forecast FDMT's earnings for 2027 to be -$200,915,491, with the lowest FDMT earnings forecast at -$277,162,249, and the highest FDMT earnings forecast at -$82,188,805.

In 2028, FDMT is forecast to generate -$227,283,328 in earnings, with the lowest earnings forecast at -$348,832,487 and the highest earnings forecast at -$121,783,412.

What is FDMT's revenue growth forecast for 2026-2028?

(NASDAQ: FDMT) 4d Molecular Therapeutics's forecast annual revenue growth rate of 544.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.25%.

4d Molecular Therapeutics's revenue in 2026 is $120,000.On average, 11 Wall Street analysts forecast FDMT's revenue for 2026 to be $1,180,639,190, with the lowest FDMT revenue forecast at $0, and the highest FDMT revenue forecast at $3,077,580,815. On average, 10 Wall Street analysts forecast FDMT's revenue for 2027 to be $1,242,973,557, with the lowest FDMT revenue forecast at $0, and the highest FDMT revenue forecast at $1,919,738,520.

In 2028, FDMT is forecast to generate $2,013,497,178 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,599,509,725.

What is FDMT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: FDMT) forecast ROA is -55.9%, which is lower than the forecast US Biotechnology industry average of 118.5%.

What is FDMT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year FDMT price target, the average FDMT price target is $32.40, with the highest FDMT stock price forecast at $38.00 and the lowest FDMT stock price forecast at $26.00.

On average, Wall Street analysts predict that 4d Molecular Therapeutics's share price could reach $32.40 by Jan 28, 2027. The average 4d Molecular Therapeutics stock price prediction forecasts a potential upside of 241.41% from the current FDMT share price of $9.49.

What is FDMT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: FDMT) 4d Molecular Therapeutics's current Earnings Per Share (EPS) is -$3.75. On average, analysts forecast that FDMT's EPS will be -$3.55 for 2026, with the lowest EPS forecast at -$4.21, and the highest EPS forecast at -$2.73. On average, analysts forecast that FDMT's EPS will be -$3.52 for 2027, with the lowest EPS forecast at -$4.85, and the highest EPS forecast at -$1.44. In 2028, FDMT's EPS is forecast to hit -$3.98 (min: -$6.11, max: -$2.13).

What is FDMT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: FDMT) forecast ROE is -64.23%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.